<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02258659</url>
  </required_header>
  <id_info>
    <org_study_id>IRB14-0639</org_study_id>
    <secondary_id>NCI-2014-01867</secondary_id>
    <secondary_id>IRB14-0639</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <nct_id>NCT02258659</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation) and carboplatin followed by response-based local therapy in treating patients&#xD;
      with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in&#xD;
      chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin,&#xD;
      hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells.&#xD;
      Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and&#xD;
      reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and&#xD;
      radiation therapy based on response (response-based therapy) and giving patients who are&#xD;
      responding well lower doses of treatment may help reduce the occurrence of side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the 2-year progression-free survival (PFS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Clinical complete response rate (nab-paclitaxel based induction, compared to European&#xD;
      Prospective Investigation into Cancer and Nutrition [EPIC] induction [paclitaxel based]).&#xD;
&#xD;
      II. Response rate (nab-paclitaxel based induction, compared to EPIC induction [paclitaxel&#xD;
      based]).&#xD;
&#xD;
      III. Proportion of patients with &gt;= 50% shrinkage by Response Evaluation Criteria In Solid&#xD;
      Tumors (RECIST) (nab-paclitaxel based induction, compared to EPIC induction, paclitaxel&#xD;
      based).&#xD;
&#xD;
      IV. Toxicity (nab-paclitaxel based induction, compared to EPIC induction [paclitaxel based]).&#xD;
&#xD;
      V. To assess swallowing function and speech at 6 months (mos) and 12 mos post therapy.&#xD;
&#xD;
      VI. To determine the rates of late toxicity with chemoradiation following surgery as&#xD;
      determined by xerostomia, dental decay, osteroradionecrosis, G-tube dependency, tracheostomy&#xD;
      placement and dysphagia.&#xD;
&#xD;
      VII. 2-year overall survival (OS) in patients treated on the Low-Risk, Intermediate-Risk Arm,&#xD;
      and High-Risk Arms.&#xD;
&#xD;
      VIII. 2-year PFS in patients treated on the Low-Risk, Intermediate-Risk Arm, and High-Risk&#xD;
      Arms - early and late toxicities.&#xD;
&#xD;
      IX. Evaluate need for post radiotherapy/chemoradiotherapy (RT/CRT) surgery on low- and&#xD;
      intermediate-risk arms based on response from induction chemotherapy.&#xD;
&#xD;
      X. Evaluate in a descriptive manner the role of transoral robotic surgery (TORS)&#xD;
      resection/lymph node dissection (LND) when integrated into a de-escalation trial.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate pathologic/histologic appearance of tumor after induction chemotherapy and&#xD;
      after CRT.&#xD;
&#xD;
      II. Translational research on blood and tissue samples. III. To profile tumors genetically&#xD;
      and immunologically in order to assess in a descriptive manner genetic or immunological&#xD;
      features characteristic of clinical behavior.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION CHEMOTHERAPY: All patients receive paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation intravenously (IV) over 60 minutes on days 1, 8, and 15 and carboplatin IV over&#xD;
      30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are then assigned to 1 of 3 treatment groups based on response to induction&#xD;
      chemotherapy.&#xD;
&#xD;
      GROUP A (LOW-DOSE ARM): Patients undergo radiation therapy once daily for 5 weeks.&#xD;
&#xD;
      GROUP B (INTERMEDIATE-DOSE ARM): Patients receive hydroxyurea orally (PO) twice daily (BID)&#xD;
      on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on&#xD;
      day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats&#xD;
      every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      GROUP C (STANDARD-DOSE ARM): Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV&#xD;
      continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive&#xD;
      standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5&#xD;
      courses in the absence of disease progression or unacceptable toxicity.*&#xD;
&#xD;
      *NOTE: At the discretion of the principal investigator (PI), patients may receive cisplatin&#xD;
      IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo&#xD;
      daily radiation therapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days, every 3 months for&#xD;
      1 year, every 6 months for 2 years, and then annually for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 22, 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS, Evaluated Using RECIST Version (v) 1.1</measure>
    <time_frame>Time from enrollment until disease progression or death from any cause, assessed at 2 years</time_frame>
    <description>If all patients are followed for two years, the PFS rate and confidence interval will be determined based on the exact binomial distribution. Otherwise PFS will be estimated using the Kaplan-Meier method and a (large-sample) one-sided 90% confidence interval will be derived for the PFS rate at two years to test the non-inferiority hypothesis. Median PFS will be estimated as described in Brookmeyer and Crowley.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Pathologic Complete Response (PCR) on Post Treatment Biopsy/Surgery, Evaluated Using RECIST v1.1</measure>
    <time_frame>Up to 8 weeks after completion of CRT</time_frame>
    <description>Pathologic response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Response by Computerized Tomography (CT) &amp; Magnetic Resonance Imaging (MRI) Only</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Clinical response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of registration to the date of death or date of last patient contact if censored, assessed up to 5 years</time_frame>
    <description>Overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall Cancer-specific survival rate. Patients dying from non-cancer related causes will be censored at the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of acute (mucositis, xerostomia, anorexia, weight loss, dermatitis and G-tube placement) toxicities will be estimated along with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Late Toxicity, Determined by Incidence of Xerostomia, Dental Decay, Osteroradionecrosis, G-tube Dependency, Tracheostomy Placement and Dysphagia</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of late-term (xerostomia, dental decay, osteroradionecrosis, G-tube dependency, speech abnormalities, tracheostomy placement and dysphagia) toxicities will be estimated along with 95% confidence intervals.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Histologic Appearance of Post-induction Tumor Tissue</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.</description>
  </other_outcome>
  <other_outcome>
    <measure>Histologic Appearance of Post-CRT Tumor Tissue</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Reactive T Cells</measure>
    <time_frame>Baseline to up to 2 months after radiation therapy</time_frame>
    <description>Changes in reactive T cells over time will be assessed using mixed effects models and simple paired t-tests.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Oropharynx</condition>
  <arm_group>
    <arm_group_label>Group A (radiation therapy alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiation therapy once daily for weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.*&#xD;
*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group A (radiation therapy alone)</arm_group_label>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>ABI-007</other_name>
    <other_name>nab paclitaxel</other_name>
    <other_name>nab-paclitaxel</other_name>
    <other_name>nanoparticle albumin-bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group A (radiation therapy alone)</arm_group_label>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Group A (radiation therapy alone)</arm_group_label>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>HU</other_name>
    <other_name>HYD</other_name>
    <other_name>Hydrea</other_name>
    <other_name>Hydroxycarbamide</other_name>
    <other_name>Hydurea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group A (radiation therapy alone)</arm_group_label>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group A (radiation therapy alone)</arm_group_label>
    <arm_group_label>Group B (combination chemotherapy, low-dose radiation therapy)</arm_group_label>
    <arm_group_label>Group C (combination chemotherapy, high-dose radiation)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have pathologically confirmed HPV-positive squamous cell carcinoma&#xD;
&#xD;
          -  HPV testing must follow the following criteria&#xD;
&#xD;
               -  HPV testing using an E6/E7 based assay is preferred, and does not require any&#xD;
                  validation (e.g. HPV in situ hybridization [ISH] or HPV E6/E7 polymerase chain&#xD;
                  reaction [PCR])&#xD;
&#xD;
               -  For oropharyngeal tumors p16 immunohistochemistry (IHC) positivity is sufficient&#xD;
                  to enroll and initiate treatment (p16 IHC interpretation to follow guidelines by&#xD;
                  Jordan/Lingen et al 2012); it is recommended that p16 IHC positivity is validated&#xD;
                  at a later point (during or after treatment) using an E6/E7 based test at the&#xD;
                  University of Chicago and provided slides will be used&#xD;
&#xD;
               -  For non-operative (OP) tumors accurate HPV testing (i.e. ISH, or E6/E7 based&#xD;
                  testing) is required for enrollment and treatment initiation&#xD;
&#xD;
          -  Availability of &gt;= 10 unstained 5 micron slides&#xD;
&#xD;
          -  Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) nodal&#xD;
             stage N2 or N3 or a T4 primary tumor&#xD;
&#xD;
          -  The primary and nodal involvement must be assessable on clinical exam (mucosal and&#xD;
             lymph node exam)&#xD;
&#xD;
          -  The primary and nodal involvement must have been defined bi- or uni-dimensional&#xD;
             measurements measurable by RECIST&#xD;
&#xD;
          -  No previous radiation or chemotherapy for a head and neck cancer&#xD;
&#xD;
          -  No surgical resection for a head and neck cancer within 8 weeks of enrollment&#xD;
             (although lymph node biopsy including excision of an individual node with presence of&#xD;
             residual nodal disease, or surgical biopsy of the tumor is acceptable)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky &gt;= 70%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3000/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 gm/dL&#xD;
&#xD;
          -  Albumin &gt; 2.9 gm/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 mg/dl&#xD;
&#xD;
          -  Creatinine clearance &gt; 45 mL/min (or serum creatinine [SCr] =&lt; 1.5 mg/dL), normal&#xD;
             within 2 weeks prior to start of treatment&#xD;
&#xD;
          -  The standard Cockcroft and Gault formula or the measured glomerular filtration rate&#xD;
             must be used to calculate creatinine clearance (CrCl) for enrollment or dosing&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 X upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 2.5 X ULN&#xD;
&#xD;
          -  Patients must sign a study-specific informed consent form prior to study entry;&#xD;
             patients should have the ability to understand and the willingness to sign a written&#xD;
             informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unequivocal demonstration of distant metastases (M1 disease)&#xD;
&#xD;
          -  Intercurrent medical illnesses which would impair patient tolerance to therapy or&#xD;
             limit survival; including but not limited to ongoing or active infection,&#xD;
             immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction,&#xD;
             cardiomyopathy, unstable angina pectoris, cardiac arrhythmia or psychiatric&#xD;
             illness/social situations that would limit compliance&#xD;
&#xD;
          -  Pregnant and nursing women are excluded; men and women of child-bearing potential are&#xD;
             eligible but must consent to using effective contraception during therapy and for at&#xD;
             least 3 months after completing therapy; women with child-bearing potential must have&#xD;
             a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at&#xD;
             screening&#xD;
&#xD;
          -  Other coexisting malignancies or malignancies diagnosed within the previous 3 years no&#xD;
             evidence of disease for at least 3 years; exceptions to this include non-melanoma skin&#xD;
             cancer, cervical cancer in situ, well differentiated thyroid cancer or prostate&#xD;
             cancer; other cancers that per assessment of the PI are not prognosis limiting can be&#xD;
             allowed after review by the PI&#xD;
&#xD;
          -  Prior surgical therapy other than incisional or excisional biopsy and organ-sparing&#xD;
             procedures such as debulking of airway-compromising tumors or neck dissection in a&#xD;
             patient with an unknown primary tumor; residual tumor is required for enrollment on&#xD;
             study&#xD;
&#xD;
          -  Patients receiving other investigational agents&#xD;
&#xD;
          -  Peripheral neuropathy &gt;= grade 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett Vokes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2014</study_first_posted>
  <results_first_submitted>December 14, 2020</results_first_submitted>
  <results_first_submitted_qc>December 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2021</results_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02258659/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="54" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PFS, Evaluated Using RECIST Version (v) 1.1</title>
        <description>If all patients are followed for two years, the PFS rate and confidence interval will be determined based on the exact binomial distribution. Otherwise PFS will be estimated using the Kaplan-Meier method and a (large-sample) one-sided 90% confidence interval will be derived for the PFS rate at two years to test the non-inferiority hypothesis. Median PFS will be estimated as described in Brookmeyer and Crowley.</description>
        <time_frame>Time from enrollment until disease progression or death from any cause, assessed at 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, Evaluated Using RECIST Version (v) 1.1</title>
          <description>If all patients are followed for two years, the PFS rate and confidence interval will be determined based on the exact binomial distribution. Otherwise PFS will be estimated using the Kaplan-Meier method and a (large-sample) one-sided 90% confidence interval will be derived for the PFS rate at two years to test the non-inferiority hypothesis. Median PFS will be estimated as described in Brookmeyer and Crowley.</description>
          <units>percentage of PFS</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="88" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Pathologic Complete Response (PCR) on Post Treatment Biopsy/Surgery, Evaluated Using RECIST v1.1</title>
        <description>Pathologic response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.</description>
        <time_frame>Up to 8 weeks after completion of CRT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Pathologic Complete Response (PCR) on Post Treatment Biopsy/Surgery, Evaluated Using RECIST v1.1</title>
          <description>Pathologic response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.</description>
          <units>percentage of PCR</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="79" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Complete Response by Computerized Tomography (CT) &amp; Magnetic Resonance Imaging (MRI) Only</title>
        <description>Clinical response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Complete Response by Computerized Tomography (CT) &amp; Magnetic Resonance Imaging (MRI) Only</title>
          <description>Clinical response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.</description>
          <units>percentage of rates</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="5.8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="68" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="5.8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival rate</description>
        <time_frame>From the date of registration to the date of death or date of last patient contact if censored, assessed up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival rate</description>
          <units>percentage of OS</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="66" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cancer-specific Survival</title>
        <description>Overall Cancer-specific survival rate. Patients dying from non-cancer related causes will be censored at the time of death.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Cancer-specific Survival</title>
          <description>Overall Cancer-specific survival rate. Patients dying from non-cancer related causes will be censored at the time of death.</description>
          <units>percentage of OS</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="85" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement</title>
        <description>Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of acute (mucositis, xerostomia, anorexia, weight loss, dermatitis and G-tube placement) toxicities will be estimated along with 95% confidence intervals.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement</title>
          <description>Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of acute (mucositis, xerostomia, anorexia, weight loss, dermatitis and G-tube placement) toxicities will be estimated along with 95% confidence intervals.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3+ mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3+ dermatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3+ neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3+ Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Late Toxicity, Determined by Incidence of Xerostomia, Dental Decay, Osteroradionecrosis, G-tube Dependency, Tracheostomy Placement and Dysphagia</title>
        <description>Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of late-term (xerostomia, dental decay, osteroradionecrosis, G-tube dependency, speech abnormalities, tracheostomy placement and dysphagia) toxicities will be estimated along with 95% confidence intervals.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Late Toxicity, Determined by Incidence of Xerostomia, Dental Decay, Osteroradionecrosis, G-tube Dependency, Tracheostomy Placement and Dysphagia</title>
          <description>Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of late-term (xerostomia, dental decay, osteroradionecrosis, G-tube dependency, speech abnormalities, tracheostomy placement and dysphagia) toxicities will be estimated along with 95% confidence intervals.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G-tube dependence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphagia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Histologic Appearance of Post-induction Tumor Tissue</title>
        <description>Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.</description>
        <time_frame>Up to 3 months post-treatment</time_frame>
        <population>zero analyzed because data were not available</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Histologic Appearance of Post-induction Tumor Tissue</title>
          <description>Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.</description>
          <population>zero analyzed because data were not available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Histologic Appearance of Post-CRT Tumor Tissue</title>
        <description>Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.</description>
        <time_frame>Up to 3 months post-treatment</time_frame>
        <population>zero analyzed because data were not available</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Histologic Appearance of Post-CRT Tumor Tissue</title>
          <description>Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.</description>
          <population>zero analyzed because data were not available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Reactive T Cells</title>
        <description>Changes in reactive T cells over time will be assessed using mixed effects models and simple paired t-tests.</description>
        <time_frame>Baseline to up to 2 months after radiation therapy</time_frame>
        <population>zero analyzed because data were not available</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Reactive T Cells</title>
          <description>Changes in reactive T cells over time will be assessed using mixed effects models and simple paired t-tests.</description>
          <population>zero analyzed because data were not available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neck edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Everett Vokes</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-9306</phone>
      <email>evokes@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

